The estimated Net Worth of James A Geraghty is at least $870 Mille dollars as of 28 June 2021. Mr. Geraghty owns over 10,000 units of Voyager Therapeutics Inc stock worth over $569,684 and over the last 11 years he sold VYGR stock worth over $0. In addition, he makes $300,591 as Independent Director at Voyager Therapeutics Inc.
Sign up
Mr. Geraghty VYGR stock SEC Form 4 insiders trading
james has made over 18 trades of the Voyager Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of VYGR stock worth $91,600 on 28 June 2021.
The largest trade he's ever made was buying 300,000 units of Voyager Therapeutics Inc stock on 19 August 2013 worth over $525,000. On average, james trades about 6,851 units every 37 days since 2013. As of 28 June 2021 he still owns at least 90,714 units of Voyager Therapeutics Inc stock.
You can see the complete history of Mr. Geraghty stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
james Geraghty biography
James A. (Jim) Geraghty is Independent Director of the Company since January 2014. He has served as Chairman of the Boards of Directors of publicly traded biopharmaceutical companies Idera Pharmaceuticals since May 2013 and Orchard Therapeutics plc since June 2018, as a member of the Boards of Directors of publicly traded biotechnology companies Pieris Pharmaceuticals, Inc. since May 2017 and Fulcrum Therapeutics, Inc. since July 2016. Mr. Geraghty was formerly Chairman of the Board of Directors of Juniper Pharmaceuticals, Inc., a biotechnology company since acquired by Catalant, Inc., from June 2015 to August 2018. He served as an Entrepreneur in Residence at Third Rock Ventures, LLC, a life sciences venture capital firm focused on the formation, development and strategy of new companies, from May 2013 to August 2017. Prior to that, Mr. Geraghty served as Senior Vice President, North America Strategy and Business Development at Sanofi S.A. from February 2011 to October 2013. Earlier, he held many roles at Genzyme Corporation from 1992 to 2011, most recently as Senior Vice President of International Development and as an executive officer. While at Genzyme, his roles included President of Genzyme Europe and General Manager of Genzyme’s cardiovascular business. Mr. Geraghty also served as Chairman, President and CEO of GTC Biotherapeutics, Inc. (formerly Genzyme Transgenics). Mr. Geraghty received a B.A. from Georgetown University, an M.S. from the University of Pennsylvania, and a J.D. from Yale Law School.
What is the salary of james Geraghty?
As the Independent Director of Voyager Therapeutics Inc, the total compensation of james Geraghty at Voyager Therapeutics Inc is $300,591. There are 6 executives at Voyager Therapeutics Inc getting paid more, with Omar Khwaja having the highest compensation of $3,815,770.
How old is james Geraghty?
james Geraghty is 65, he's been the Independent Director of Voyager Therapeutics Inc since 2014. There are 4 older and 11 younger executives at Voyager Therapeutics Inc. The oldest executive at Voyager Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the Exec. Science Advisor & Director.
What's james Geraghty's mailing address?
James's mailing address filed with the SEC is C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Voyager Therapeutics Inc
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 e Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
What does Voyager Therapeutics Inc do?
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
What does Voyager Therapeutics Inc's logo look like?
Complete history of Mr. Geraghty stock trades at Idera Pharmaceuticals, Pieris Pharmaceuticals Inc, Voyager Therapeutics Inc, Orchard Therapeutics plc e Fulcrum Therapeutics Inc
Voyager Therapeutics Inc executives and stock owners
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Omar Khwaja,
Chief Medical Officer and Head of Research and Development -
Robert Hesslein,
Senior Vice President, General Counsel -
G. Andre Turenne,
President, Chief Executive Officer, Director -
G. Andre Turenne,
Advisor -
Dr. Omar Khwaja M.D., Ph.D.,
Chief Medical Officer and Head of R&D -
Robert W. Hesslein,
Sr. VP & Gen. Counsel -
james Geraghty,
Independent Director -
Steven Hyman,
Independent Director -
Michael J. Higgins M.B.A.,
Interim CEO, Pres & Chairman -
Dr. Glenn F. Pierce M.D., Ph.D.,
Independent Director, Interim Chief Scientific Officer & Chief Medical Officer -
Dr. Steven M. Paul M.D.,
Exec. Science Advisor & Director -
Nancy Vitale,
Director -
Michelle Smith,
Chief Human Resource Officer -
Kelly Bales,
Senior Vice President, Head of Neuroscience -
Allison Dorval,
Chief Financial Officer -
Robin Swartz,
Chief Operating Officer -
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.,
Pres, CEO & Director -
Julie Burek,
VP of Fin. -
Dr. Mark A. Kay M.D., Ph.D.,
Founder -
Dr. Phillip D. Zamore,
Founder -
Dr. Mark A. Kay,
Founder -
Dr. Guangping Gao,
Founder -
Dr. Krystof Bankiewicz M.D., Ph.D.,
Founder -
Toby Ferguson,
Chief Medical Officer -
Sandell Jacquelyn Fahey,
Chief Legal Officer -
Rock Ventures Iii, L.P.Thir...,
-
Jane Henderson,
Sr. V.P. & CFO, Corp. Dev. -
Wendy L Dixon,
Director -
Jeff Goater,
Chief Financial Officer -
Sanofi,
-
Perry A Karsen,
Director -
Harbor Master Investors (Ca...,
10% owner -
Bernard Ravina,
Chief Medical Officer -
Matthew P. Ottmer,
Chief Operating Officer -
Dinah Ph.D. Sah,
Chief Scientific Officer -
Steven M Paul,
Director -
Andre Turenne,
President & CEO -
Robin Swartz,
Chief Operating Officer -
Biosciences Inc Neurocrine,
10% owner -
Michael J Higgins,
Director -
Mark J Levin,
Director -
Glenn Pierce,
Director -
Julie Burek,
VP, Finance -
Todd Alfred Carter,
Chief Scientific Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Rock Ventures Iii, L.P.Thir...,
-
Catherine J Mackey,
Director -
Jude Onyia,
Director -
Grace Colon,
Director -
Capital, Llc Eco R1,
10% owner -
George A Scangos,
Director -
Nathan D. Jorgensen,
Chief Financial Officer